Biotechnology
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...
2022-11-22 04:59
3769
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreeme...
2022-11-21 19:00
3374
OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION
"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality"Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by th...
2022-11-21 18:00
2961
Genotek (Yerevan, Armenia), Professor Tamara Sarkisian and Illumina open a world-class genomic laboratory
Yesterday, the genetic laboratory Genotek started to work in Yerevan, Armenia. The main goal is to provide the people of the region with affordable and modern medical technologies and to create new varieties of agricultural plants and animals. YEREVAN, Armenia, Nov. 19, 2022 /PRNewswire/ -- The ...
2022-11-19 03:30
11477
GenScript takes home Executive of the Year - Biotechnology at the SBR Management Excellence Awards 2022
Mr. Johnson Wang has propelled the GenScript APAC team to achieve numerous milestones despite external challenges. SINGAPORE, Nov. 18, 2022 /PRNewswire/ -- Global biotechnology corporation, GenScript Asia Pacific's President, Mr.Johnson Wang bagged the Executive of the Year - Biotechnology title...
2022-11-18 15:23
7494
Asa Ren and G42 Healthcare Team Up to Advance Genomic Sequencing and Bioinformatics in Indonesia
JAKARTA, Indonesia, Nov. 17, 2022 /PRNewswire/ -- Asa Ren Pte Ltd ("Asa Ren"), a leading consumer DNA data company based inIndonesia, has announced a strategic partnership with leading UAE-based Artificial Intelligence technology company, G42 Health Care AI Holding RSC LTD ("G42 Healthcare"). Th...
2022-11-17 19:49
4141
In operation the most innovative 11.74T MRI Core Magnet to be used on humans
GENOA, Italy, Nov. 17, 2022 /PRNewswire/ -- The world's first simultaneous multi-channel/multi-nuclear 11.74T MRI system is currently under development at Gachon University Gil Medical Center (GUGMC). In the first Half of 2022 GUGMC successfully completed the Site Acceptance Test of the Magne...
2022-11-17 16:25
4443
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced onNovember 5 that the Company's self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been offi...
2022-11-17 08:00
4039
BDT Capital Partners acquires minority stake in Exyte
* Partnership will enhance Exyte's long-term strategy as the world leader in the design, engineering, and delivery of high-tech facilities * Exyte serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers; industries offerin...
2022-11-16 21:31
5315
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021
VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...
2022-11-16 21:00
5562
Imaging Endpoints Announces the Appointment of Joy (Huan) Zhu, M.D., Ph.D., as Vice President, Medical Operations
SCOTTSDALE, Ariz., Nov. 16, 2022 /PRNewswire/ -- Imaging Endpoints (IE), the world's largest oncology-focused imaging CRO, announced today the addition of Joy (Huan) Zhu, M.D., Ph.D., to the company as Vice President, Medical Operations. Prior to joining IE, Joy spent 25 years in oncology clinica...
2022-11-16 21:00
3547
MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System
MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VA...
2022-11-16 19:55
3466
YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent to European Union GMP
GAITHERSBURG, Maryland, Nov. 16, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics, today announced that...
2022-11-16 08:50
3068
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-m...
2022-11-15 20:30
2389
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status * Study builds on promising results of Phase II TORCH monotherapy study in HBV+ p...
2022-11-15 16:51
2779
Striving Together, Upgrading the Biopharma Industry - International Biopharma Industry Week Shanghai 2022 Kicks Off
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- On November 14, the opening ceremony of the second "International Biopharma Industry Week Shanghai" (hereinafter referred to as the "IBIWS 2022") took place in the Shanghai Zhangjiang Science Hall. Themed on "Striving Together, Upgrading the Biopharma Indus...
2022-11-15 14:17
3291
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa * Early customers include GP offices and other community-based healthcare settings * Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly ...
2022-11-14 23:24
3335
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) an...
2022-11-14 20:06
3637
SENTINEL DIAGNOSTICS LAUNCHES SENTINAT® 200, THE FULLY AUTOMATED SAMPLE TO RESULT SYSTEM FOR THE DIAGNOSIS OF VIRAL INFECTIONS
MILAN, Nov. 14, 2022 /PRNewswire/ -- Sentinel CH. SpA today announced the launch ofSENTiNAT® 200, the fully automated sample to result system, and STAT-NAT® SN200 Real-Time PCR assays for the quantitative detection of 10 viruses.SENTiNAT® 200 and STAT-NAT® SN200 kits represent the ideal soluti...
2022-11-14 17:00
2894
Telix Acquires Optimal Tracers
MELBOURNE, Australia and INDIANAPOLIS, Ind., Nov. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement withSacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochem...
2022-11-14 06:36
4013
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 314 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 283 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
8252
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8008
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026-06-05 22:00
7476
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
7363
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
6990